Additional support for prexasertib as a clinical trial agent for MYBL2 High lung adenocarcinomas is provided by a Phase 2 clinical trial recently carried out in high grade serous ovarian cancer (HGSOC) (48). Here, MYBL2 is linked to lung adenocarcinoma.